U. Sahin

PS5-09-20: A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01)

P. Schmid, R. Dent, Pedram Razavi, P. Rietschel et autres

Abstract Background: TNBC, accounting for 15-25% of breast cancer cases, is an aggressive subtype with poor prognosis, and metastatic TNBC remains challenging to treat with current standard of care (SOC). PD-(L)1 inhibitors combined with chemo have improved outcomes in pts with high …

gb, sg, us, de (code pays fourni par la source)

Contributors

Emily Affolter, Jagger Alexander, Marcalee Alexander, Amina Rahma Audu et autres

us, jp, au, ca, lk, np (code pays fourni par la source)

MA01.07 Preliminary Results of the Phase I LuCa-MERIT-1 Trial: An Advanced NSCLC pt Cohort Treated With BNT116 + Cemiplimab Post CRT

Bala Başak Öven, D. Vicente Baz, J. Alt, E. Felip Font et autres

tr, es, de, us (code pays fourni par la source)

999MO HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma

C.H.H. Ottensmeier, Elizabeth A. King, S. Crabb, Ioannis Karydis et autres

gb, de, us (code pays fourni par la source)

175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors

Ignacio Melero, E. Grande Pulido, M.L. Johnson, J.R. Bauman et autres

GEN1042 (DuoBody-CD40x4-1BB) is an investigational, novel, agonistic bispecific antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells. GEN1042 demonstrated biologic and early clinical activity with a manageable safety profile in patients (pts) with advanced solid tumors in …

es, us, de (code pays fourni par la source)